CFFT Awards $3 million to Polyphor to Test Anti-Inflammatory Drug

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.

| 2 min read

The award will support clinical testing through the end of 2017. Specifically, Polyphor has initiated a Phase I trial and plans to evaluate the safety of POL6014 in individuals with CF. Once this is complete, the company will begin a 28-day trial to assess the drug's effectiveness. 

POL6014 reduces the activity of neutrophil elastase, a type of enzyme that is released by white blood cells to fight lung infections. In healthy people, these enzymes destroy the proteins that make up the structure of bacteria and eliminate the threat of infection. In individuals with CF, an excessive amount of neutrophil elastase is produced and begins to damage the proteins that make up the structure of healthy airway tissue

Over time, this infection-inflammation cycle can weaken the walls of the airways and eventually lead to respiratory failure.

CFFT is the Cystic Fibrosis Foundation's nonprofit drug discovery and development affiliate, created to help speed development of new cystic fibrosis treatments by funding promising scientific research. 

POL6014 is taken using an aerosol inhaler.

Read the Polyphor press release.

Share this article
Topics
Research
Recent news
Teens Advocate for the PASTEUR Act as Part of the CF Foundation’s 14th Annual Teen Advocacy Day
News | 4 min read
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe